



Continuation of Substance of Interview including description of the general nature of what was discussed: Mr. Termes was contacted with an examiner's amendment to place the application in condition for allowance. The amendment requested included incorporation of SEQ ID NOs. to peptide sequences recited in claims 442 and 446 and a terminal disclaimer over the copending US application 10/583,464. Mr. Terme informed the office that the amendments would be filed after consultation with applicants. Mr. Termes was again contacted on 12/21/10 and 1/14/11 to discuss the status of the application. Mr. Termes on 1/14/11 indicated that discussions to file a TD over the copending application requires additional time and hence a final office action from the office is appropriate..